FDA Approves Nivolumab with Ipilimumab for Unresectable or Metastatic MSI-H or dMMR Colorectal Cancer By Ogkologos - May 9, 2025 562 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the CHECKMATE-8HW study Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR 癌症可以在家族成员中被遗传吗？ October 13, 2020 Pembrolizumab Approved for Some Patients with Advanced Esophageal Cancer August 28, 2019 Surprise! Financial Assistance To Help With Your Medical Bills May Be... December 20, 2023 Commemorating and Making History: The National Cancer Act 50th Anniversary February 8, 2021 Load more HOT NEWS 25-Year-Old Mom Had Chemo & Surgery, Then Was Told She Never... EMA Recommends Extension of Therapeutic Indications for Nivolumab and Ipilimumab to... EMA Recommends Extending Indications for Zanubrutinib to Include Treatment of Patients... New breast and lung cancer treatments approved in Scotland
